Literature DB >> 22058280

The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

Sylvie Hermouet, Mathias Vilaine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22058280      PMCID： PMC3208673          DOI： 10.3324/haematol.2011.055392

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Authors:  Eric Lippert; Marjorie Boissinot; Robert Kralovics; François Girodon; Irène Dobo; Vincent Praloran; Nathalie Boiret-Dupré; Radek C Skoda; Sylvie Hermouet
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

3.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.

Authors:  Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmada; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephan R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; Jean-Pierre Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwilliam; Mark Tremelling; Panos Deloukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly
Journal:  Nat Genet       Date:  2008-06-29       Impact factor: 38.330

4.  JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.

Authors:  C Cleyrat; J Jelinek; F Girodon; M Boissinot; T Ponge; J-L Harousseau; J-P Issa; S Hermouet
Journal:  Leukemia       Date:  2010-02-25       Impact factor: 11.528

5.  In vitro differentiation of bone marrow stromal cells into neurons and glial cells and differential protein expression in a two-compartment bone marrow stromal cell/neuron co-culture system.

Authors:  Xu Qi; Ming Shao; Haisheng Peng; Zhenggang Bi; Zhiqiang Su; Hulun Li
Journal:  J Clin Neurosci       Date:  2010-04-08       Impact factor: 1.961

6.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

7.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

8.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Authors:  Ralph Tiedt; Hui Hao-Shen; Marta A Sobas; Renate Looser; Stephan Dirnhofer; Jürg Schwaller; Radek C Skoda
Journal:  Blood       Date:  2007-12-26       Impact factor: 22.113

9.  Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

Authors:  Animesh Pardanani; Brooke L Fridley; Terra L Lasho; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

10.  JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

Authors:  A Tefferi; T L Lasho; M M Patnaik; C M Finke; K Hussein; W J Hogan; M A Elliott; M R Litzow; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2009-10-22       Impact factor: 11.528
View more
  25 in total

1.  The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

Authors:  Xinju Zhang; Tingting Hu; Zhiyuan Wu; Zhihua Kang; Weiwei Liu; Ming Guan
Journal:  Int J Hematol       Date:  2012-09-29       Impact factor: 2.490

2.  Polymorphisms in immune mediators associate with risk of cervical cancer.

Authors:  Zhengyan Zhang; Samantha Fye; Ingrid B Borecki; Janet S Rader
Journal:  Gynecol Oncol       Date:  2014-08-12       Impact factor: 5.482

3.  Genetic effects of single nucleotide polymorphisms in JAK2 and STAT5A genes on susceptibility of Chinese Holsteins to mastitis.

Authors:  Tahir Usman; Ying Yu; Chao Liu; Xiao Wang; Qin Zhang; Yachun Wang
Journal:  Mol Biol Rep       Date:  2014-09-10       Impact factor: 2.316

Review 4.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.

Authors:  Jan Habbel; Lucas Arnold; Yiyang Chen; Michael Möllmann; Kirsten Bruderek; Sven Brandau; Ulrich Dührsen; Maher Hanoun
Journal:  Blood Adv       Date:  2020-07-14

6.  Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.

Authors:  Ann-Kathrin Eisfeld; Guido Marcucci; Sandya Liyanarachchi; Konstanze Döhner; Sebastian Schwind; Kati Maharry; Benjamin Leffel; Hartmut Döhner; Michael D Radmacher; Clara D Bloomfield; Stephan M Tanner; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

7.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

8.  Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.

Authors:  Hew Yeng Lai; Stefan A Brooks; Brianna M Craver; Sarah J Morse; Thanh Kim Nguyen; Nahideh Haghighi; Michael R Garbati; Angela G Fleischman
Journal:  Blood Adv       Date:  2019-01-22

9.  Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.

Authors:  Hans Carl Hasselbalch; Mads Thomassen; Caroline Hasselbalch Riley; Lasse Kjær; Thomas Stauffer Larsen; Morten K Jensen; Ole Weis Bjerrum; Torben A Kruse; Vibe Skov
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

10.  JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines.

Authors:  P Nauroy; F Delhommeau; F Baklouti
Journal:  Blood Cancer J       Date:  2014-06-27       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.